EVCLX | SAUPX | EVCLX / SAUPX | |
Total Expense Ratio | 1.01 | 1.00 | 101% |
Annual Report Gross Expense Ratio | 1.08 | 1.00 | 108% |
Fund Existence | 9 years | 29 years | - |
Gain YTD | 3.665 | 2.980 | 123% |
Front Load | N/A | 4% | - |
Min. Initial Investment | 10000 | 1000 | 1,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 48.9M | 2.23B | 2% |
Annual Yield % from dividends | 3.82 | 2.79 | 137% |
Returns for 1 year | 6.33 | 6.22 | 102% |
Returns for 3 years | 18.35 | 19.11 | 96% |
Returns for 5 years | 9.75 | 13.49 | 72% |
Returns for 10 years | N/A | 25.67 | - |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FIJYX | 29.22 | -0.19 | -0.65% |
Fidelity Advisor Biotechnology Z | |||
AMDWX | 13.29 | -0.17 | -1.26% |
Amana Developing World Investor | |||
DNLDX | 59.56 | -0.77 | -1.28% |
BNY Mellon Active MidCap A | |||
RTNSX | 13.04 | -0.17 | -1.29% |
Russell Inv Tax-Managed Intl Eq S | |||
RYWAX | 49.80 | -0.93 | -1.83% |
Rydex S&P SmallCap 600 Pure Growth H |